Abstract
Cancer metastasis is represented by migration and invasion of cancer cells. Cancer cells invade into the blood or lymphatic vessels and this leads to the spread of cancer into the organs in distant sites. For cancer cells to migrate, extracellular matrix (ECM) must be degraded. Cantharidin, a compound derived from blister beetles, is known for its anti-cancer effect in several cancer cells. Here we report that cantharidin inhibits migration and invasion of A549 human lung cancer cell. We found that cantharidin inhibits activation of phosphatidylinositol 3-kinase/Akt signaling pathway. This leads to the selective attenuation of one of the gelatinases, matrix metalloproteinase 2, which can degrade components of ECM, and inhibits migration and invasion of A549 human lung cancer cell.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Attiga, F.A., P.M. Fernandez, A.T. Weeraratna, M.J. Manyak, and S.R. Patierno. 2000. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Research 60: 4629–4637.
Bae, I.H., M.J. Park, S.H. Yoon, S.W. Kang, S.S. Lee, K.M. Choi, and H.D. Um. 2006. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Research 66: 4991–4995.
Basset, P., A. Okada, M.P. Chenard, R. Kannan, I. Stoll, P. Anglard, J.P. Bellocq, and M.C. Rio. 1997. Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications. Matrix Biology 15: 535–541.
Carnero, A., C. Blanco-Aparicio, O. Renner, W. Link, and J.F. Leal. 2008. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Current Cancer Drug Targets 8: 187–198.
Chen, Y.J., W.M. Chang, Y.W. Liu, C.Y. Lee, Y.H. Jang, C.D. Kuo, and H.F. Liao. 2009. A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chemico-Biological Interactions 181: 440–446.
Chu, S.C., D.N. Hu, S.F. Yang, P.Y. Yang, Y.S. Hsieh, S.M. Huang, G. Yu, and S.A. McCormick. 2004. Uveal melanocytes produce matrix metalloproteinases-2 and -9 in vitro. Pigment Cell Research 17: 636–642.
Deryugina, E.I., and J.P. Quigley. 2006. Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews 25: 9–34.
Huang, C., K. Jacobson, and M.D. Schaller. 2004. MAP kinases and cell migration. Journal of Cell Science 117: 4619–4628.
Johnsen, M., L.R. Lund, J. Rømer, K. Almholt, and K. Danø. 1998. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Current Opinion in Cell Biology 10: 667–671.
Kok, S.H., C.H. Chui, W.S. Lam, J. Chen, F.Y. Lau, G.Y. Cheng, R.S. Wong, P.P. Lai, T.W. Leung, J.C. Tang, and A.S. Chan. 2006. Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. International Journal of Molecular Medicine 17: 945–949.
Li, W., L. Xie, Z. Chen, Y. Zhu, Y. Sun, Y. Miao, Z. Xu, and X. Han. 2010. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Science 101: 1226–1233.
Massicot, F., H. Dutertre-Catella, C. Pham-Huy, X.H. Liu, H.T. Duc, and J.M. Warnet. 2005. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and norcantharidin. Basic Clinical Pharmacology and Toxicology 96: 26–32.
Nelson, A.R., B. Fingleton, M.L. Rothenberg, and L.M. Matrisian. 2000. Matrix metalloproteinases: Biologic activity and clinical implications. Journal of Clinical Oncology 18: 1135–1149.
Nyberg, P., T. Salo, and R. Kalluri. 2008. Tumor microenvironment and angiogenesis. Frontiers in Bioscience 13: 6537–6553.
Sahai, E. 2007. Illuminating the metastatic process. Nature Reviews Cancer 7: 737–749.
Sato, H., and M. Seiki. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395–405.
Van den Steen, P.E., B. Dubois, I. Nelissen, P.M. Rudd, R.A. Dwek, and G. Opdenakker. 2002. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Critical Reviews in Biochemistry and Molecular Biology 37: 375–536.
Vivanco, I., and C.L. Sawyers. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer 2: 489–501.
Westermarck, J., and V.M. Kähäri. 1999. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB Journal 13: 781–792.
Zhan, Y.P., X.E. Huang, J. Cao, Y.Y. Lu, X.Y. Wu, J. Liu, X. Xu, L. Xu, J. Xiang, and L.H. Ye. 2012. Clinical study on safety and efficacy of quinin® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pacific Journal of Cancer Prevention 13: 4773–4776.
Acknowledgments
We thank Young Joo Lee for her technical supports. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology of Korea (2010-0023292).
Author information
Authors and Affiliations
Corresponding author
Additional information
Young Min Kim, Min Jeong Ku have contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kim, Y.M., Ku, M.J., Son, YJ. et al. Anti-metastatic effect of cantharidin in A549 human lung cancer cells. Arch. Pharm. Res. 36, 479–484 (2013). https://doi.org/10.1007/s12272-013-0044-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-013-0044-3